Retinal Vascular Changes in Pre-Diabetes and Prehypertension
New findings and their research and clinical implications
- Thanh Tan Nguyen, MBBS1,
- Jie Jin Wang, MMED, PHD12 and
- Tien Yin Wong, MD, PHD13
- 1Centre for Eye Research Australia, University of Melbourne, Victoria, Australia
- 2Centre for Vision Research, University of Sydney, New South Wales, Australia
- 3Singapore Eye Research Institute, National University of Singapore, Singapore
- Address correspondence and reprint requests to Tien Yin Wong, MD, PhD, Centre for Eye Research Australia, University of Melbourne,
32 Gisborne St., Victoria 3002, Australia. E-mail: twong{at}unimelb.edu.au
The retinal vasculature can be viewed directly and noninvasively, offering a unique and easily accessible “window” to study
the health and disease of the human microcirculation in vivo. In the last decade, advances in digital retinal photography
and imaging techniques have allowed precise characterization of subtle retinal vascular changes in large populations. These
retinal changes can be broadly divided into four groups: 1) classic retinal vascular changes in diabetes and hypertension (i.e., diabetic and hypertensive retinopathy), 2) isolated retinopathy signs in individuals with diabetes or hypertension (e.g., microaneurysm, retinal hemorrhage, or cotton
wool spot), 3) changes in retinal vascular caliber, and 4) changes in retinal vascular architecture (e.g., retinal tortuosity).
New studies in large populations now show that retinal vascular changes are common in the general population and may precede
the subsequent development of overt diabetes and hypertension. A consistent pattern of associations is also emerging, showing
that specific retinal vascular changes may be related differently to hyperglycemia and blood pressure.
In this review, we summarize recent studies on the retinal vascular changes seen in diabetes and hypertension and speculate
on potential research and clinical implications.
CLASSIC RETINAL VASCULAR CHANGES
Diabetic retinopathy
In individuals with diabetes, the classic primary retinal vascular complication—diabetic retinopathy—is well described (1). Diabetic retinopathy signs are broadly divided into nonproliferative and proliferative retinopathy. The prevalence of diabetic
retinopathy increases with duration of diabetes. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab) showed that
the prevalence of diabetic retinopathy is less than 10% in those with diabetes duration of less than 5 years but more than
50% in those with 20 years or longer diabetes (2). The two major risk factors of diabetic retinopathy are hyperglycemia and hypertension, with hyperlipidemia as a possible
third major risk factor. The importance of hyperglycemia has been confirmed in epidemiological studies (3), as well as two pivotal clinical trials: the DCCT (Diabetes Control and Complications Trial) in patients with type 1 diabetes
(4) and the UKPDS (UK Prospective Diabetes Study) in patients with type 2 diabetes (5). The UKPDS also showed that blood pressure control reduces the risk of retinopathy independent of glycemia levels (6). New data from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) Study now suggest that lipid-lowering
therapy may also reduce retinopathy requiring laser treatment (7).
Hypertensive retinopathy
Like diabetic retinopathy, classic hypertensive retinopathy is well characterized. The clinical signs include generalized
and focal arteriolar narrowing, arterio-venous nicking, increased retinal arteriolar light reflex (copper or silver wiring),
flame- and blot-shaped retinal hemorrhages, cotton wool spots, and, in severe cases, optic disc swelling (8,9). The association of these retinal signs with blood pressure is consistent and seen in both adults (10–20) and children (21), even in individuals without clinical hypertension (13–15,22–24).
ADVANCES IN ASSESSING RETINAL VASCULAR CHANGES—
Digital retinal photography and new imaging technology have now allowed more precise assessment of the subtle changes seen
in the retinal microvasculature (22,25–28). One key development has been methods to objectively quantify retinal vascular caliber. Historically, narrowed retinal arteriolar
caliber, an early hypertensive retinopathy sign, has been difficult to measure using the clinical ophthalmoscope (29). Parr, Hubbard, and colleagues (22,30,31) developed techniques to measure retinal vascular caliber from photographs and summarized these as the arterio-venous ratio
(AVR). These techniques are now used in large epidemiological studies (20,22,25,27,28) and have substantial reproducibility.
Recent studies suggest the interpretation of the AVR may be overly simplistic. A smaller AVR was thought to reflect generalized
retinal arteriolar narrowing, since venular caliber was assumed to be relatively constant (22). Thus, when a low AVR was associated with elevated blood pressure (18,32) and cardiovascular outcomes such as stroke (33,34) and coronary heart disease (35), the associations were initially thought to reflect generalized arteriolar narrowing. Newer analyses, however, suggest a
smaller AVR may not only reflect narrower arterioles but also wider venules (36,37). Furthermore, arteriolar and venular calibers appear to reflect different pathophysiological processes (37,38).
Liew et al. (38,39) have suggested the need to control for venular caliber in statistical models of arteriolar caliber, and vice versa, as venular
caliber explains ∼30% of the variability in arteriolar caliber (38)—presumably from shared genetic and ocular factors (22).
Improvements in imaging software have also led to quantification of other architectural changes in the retinal vascular network
(36,37), as well as “batch processing” of retinal images (20,22,25,27,28). There remain technical challenges. For example, the impact of magnification error (i.e., eyes of different refraction)
requires further study (40).
ISOLATED RETINOPATHY SIGNS
Epidemiology
There is increasing evidence that typical lesions of diabetic retinopathy (microaneurysms, hemorrhages, and cotton wool spots),
termed isolated retinopathy signs, are now recognized to be more common than previously thought in people without diabetes
and hypertension (41–43). Recent studies using retinal photography to document these signs suggest prevalence rates in the general population of
5–10% (2,13–15,22–24,44) (Fig. 1A) and 2.6–8.6% among those without diabetes or hypertension (13–15,22–24) (Fig. 1B). Prospective study data have further shown that up to 10% of individuals aged ≥40 years without diabetes may develop these
isolated retinopathy signs within 5 years (16,45).
Two studies have reported on the prevalence of retinopathy in individuals with pre-diabetes. In the AusDiab Study, retinopathy
signs were seen in 6.7% of individuals with impaired glucose tolerance or impaired fasting glucose (46), whereas in the Diabetes Prevention Program this was seen in 7.9% of individuals with impaired fasting glucose (5.3–6.9
mmol/l) or impaired glucose tolerance, who had no history of diabetes (47).
These isolated retinopathy signs may be transient. Population studies show that between 40 and 70% of these isolated retinopathy
signs seen at baseline are not present 3–5 years later (45,48).
Risk factors and pathophysiology
The underlying risk factors and pathophysiology of isolated retinopathy signs in nondiabetic and normotensive individuals
are poorly understood. Associations of these retinopathy signs with increasing age (15,45), elevated blood pressure (8,13–15,44,47–49), and hyperglycemia (24,44,47,48) have been found. Other possible risk factors include hyperlipidemia (17,23,48), higher BMI (23,24), and systemic inflammation (48,50). We can speculate that isolated retinopathy signs in normotensive and nondiabetic individuals may represent early microvascular
damage from a combination of risk factors, including blood pressure and abnormal glucose metabolism, which may reflect an
underlying process of developing clinical diabetes or hypertension.
Animal models and human studies suggest that chronic inflammation and glucose-induced arteriolar endothelial dysfunction are
related to development of classic diabetic retinopathy (51–53). The association of inflammation and signs of isolated retinopathy in people without diabetes (50) supports the hypothesis that inflammatory processes may also be a possible pathway that underlies early subclinical microvascular
disease in the pre-diabetes or prehypertension state.
Associations with risk of diabetes, hypertension, and cardiovascular diseases
A clinically relevant question is whether signs of isolated retinopathy in individuals without diabetes are markers of the
future risk of diabetes (i.e., do these patients require monitoring for the development of diabetes). The evidence here is
not consistent. While previous studies suggest that detectable retinopathy precedes the onset of type 2 diabetes by 4–7 years
(54), new prospective data from the Blue Mountains (45,55), the Atherosclerosis Risk In Communities (ARIC) (56), and Beaver Dam (57) studies reported no increased risk of diabetes in nondiabetic individuals with signs of retinopathy. However, there are
two notable exceptions. First, in the Beaver Dam Study, among individuals aged <65 years at baseline, signs of retinopathy
were associated with an increased 15-year incidence of diabetes (odds ratio [OR] 3.68 [95% CI 1.23–10.96]) (57). Second, in the ARIC Study, among participants with a family history of diabetes, signs of retinopathy were also associated
with an increased 3-year risk of diabetes (2.3 [1.0–5.3]) (56). Thus, the literature suggests that isolated signs of retinopathy in individuals without diabetes are not necessarily markers
of future diabetes risk, except possibly in younger individuals and in those with a family history of diabetes.
Similarly, there is conflicting evidence that isolated signs of retinopathy are markers of future hypertension risk. Data
from the Beaver Dam Study showed that among nonhypertensive individuals, those with signs of retinopathy had a higher incidence
of hypertension (OR 1.48 [95% CI 1.05–2.07]) (57), but these findings are not supported by other studies (15,45,58).
There is now substantial evidence that isolated microaneurysms, hemorrhages, and cotton wool spots predict the development
of clinical cardiovascular and cerebrovascular events independent of traditional risk factors (Table 1). Various population-based studies have shown associations of isolated signs of retinopathy with the risk of stroke (33), congestive heart failure (59), renal dysfunction (60,61), and measures of atherosclerosis (14,62,63). In the ARIC Study, the presence of retinopathy was associated with a threefold higher risk of congestive heart failure
in those without previous coronary heart disease (relative risk 2.98 [95% CI 1.50–5.92]) (59). This later association suggests that microvascular disease may be important in the development of diabetic cardiomyopathy
in the absence of established coronary artery disease.
RETINAL VASCULAR CALIBER—
The associations and clinical significance of early retinal vascular caliber changes in individuals with diabetes and pre-diabetes,
as well as hypertension and prehypertension, are summarized in Table 1.
Associations with diabetes and pre-diabetes
Consistent associations of retinal venular caliber with hyperglycemia, diabetes, and its complications are now emerging (20). Prospective data from three population-based cohorts have shown that changes in retinal vascular caliber may predict the
development of type 2 diabetes (64,65) and impaired fasting glucose (66). In two early analyses, an association between smaller retinal AVR and incident diabetes was found in the ARIC Study (OR
1.71 [95% CI 1.13–2.57]; comparing smallest to largest AVR quintile) and the Beaver Dam Study (1.53 [1.03–2.27]; comparing
smallest to largest AVR quartile) (64,65). Subsequently, the Rotterdam Study demonstrated that these associations reflected wider retinal venular caliber rather than
narrower arteriolar caliber (1.23 [1.02–1.47]; per SD increase in venular caliber) (66). Reanalysis of the ARIC and Beaver Dam studies confirms this finding (T.Y.W., unpublished data). Thus, it appears that wider
retinal venular caliber is a marker of chronic hyperglycemia and the pre-diabetes state and reflects the early microvascular
changes that occur in the development of diabetes.
Wider retinal venular caliber has also been linked to the metabolic syndrome and its components (20,37,67). In the Blue Mountains Study, wider retinal venular caliber was associated with the 5-year incidence of obesity among individuals
of normal weight at baseline (OR 1.8 [95% CI 1.0–3.1]; comparing largest to lowest venular caliber quintile) (68). Similarly, in children aged 6–8 years, wider retinal venular caliber was also associated with higher BMI (69), suggesting that retinal venular caliber may be influenced by metabolic disorders early in life. There is also evidence
that wider venular caliber is associated with various microvascular complications of diabetes, not only diabetic retinopathy
(70,71) but also diabetic nephropathy (72).
Despite these observations, the pathophysiological processes underlying the association of wider retinal venular caliber with
hyperglycemia, diabetes, and its complications are unclear. It has been speculated that retinal venular widening may be the
result of increased blood flow associated with hyperglycemia (73) and retinal hypoxia (74). Alternatively, it may also reflect inflammatory processes implicated in the pathogenesis of impaired glucose metabolism
(75), supported by epidemiological findings of wider retinal venules with elevated systemic inflammatory markers (17,20,37,76). Experiments have demonstrated that local inflammatory processes lead to wider retinal venular calibers. For example, administration
of lipid hydroperoxide in the vitreous of rats leads to an increase in the retinal venular diameter (77). Similarly, administration of Escherichia coli endotoxin in human eyes has been reported to increase retinal venular diameter (78). Finally, retinal venular dilation may be related to endothelial dysfunction, reflecting an increased production of nitric
oxide (79) secondary to higher levels of cytokines (80), seen often in association with impaired glucose metabolism (81,82) and diabetes (81).
Associations with hypertension and prehypertension
In distinct contrast to the association of hyperglycemia with retinal venular caliber, there is now substantial evidence that
hypertension preferentially affects retinal arteriolar caliber (83) (Table 1). It has long been known that generalized retinal arteriolar narrowing is an early characteristic sign of hypertensive retinopathy
(8,84,85). More recent studies using quantitative measurements of retinal vascular caliber have now demonstrated a graded association
of narrowed retinal arterioles with increasing blood pressure in different populations of various racial/ethnic groups and
age-groups (10,20,22,24,32,37,86,87).
Of greater significance are prospective findings from four populations that show retinal arteriolar narrowing is a preclinical
marker of hypertension risk. The ARIC Study (OR 1.62 [95% CI 1.21–2.18]; comparing smallest to largest AVR quintile) (58), the Beaver Dam Study (1.82 [1.39–2.40]; comparing smallest to largest AVR quartile) (88), the Blue Mountains Study (2.6 [1.7–3.9]; comparing smallest to largest arteriolar caliber quintile) (89), and the Rotterdam Study (1.38 [1.23–1.55]; per SD decrease in arteriolar caliber) (90) all reported that among individuals without hypertension at baseline, those with narrowed retinal arterioles had a higher
risk of hypertension in the subsequent 3–10 years, independent of baseline blood pressure levels, BMI, and other known hypertension
risk factors.
These observations support the hypothesis that peripheral vascular resistance, reflected by retinal arteriolar narrowing,
is an important contributing factor for hypertension development (91). Added support to this hypothesis comes from a recent genome-wide linkage analysis from the Beaver Dam Study, which demonstrated
that associations of retinal arteriolar diameter to multiple genetic loci are linked to regulation of blood pressure, endothelial
function, and vasculogenesis (92). Thus, retinal arteriolar narrowing may be considered a surrogate marker of an individual's genetic predisposition to hypertension
development (93).
Finally, a recent study has shown that the association between higher blood pressure and retinal arteriolar narrowing is detectable
in healthy children aged 6–8 years (21), reinforcing the concept that the effects of higher childhood blood pressure may have an adverse effect on the microcirculation
(94,95).
Associations with cardiovascular diseases
In addition to their associations with diabetes and hypertension, changes in retinal vascular caliber have also been linked
to a range of cardiovascular diseases (Table 1). Wider retinal venular caliber has been associated with carotid artery disease (37), magnetic resonance imaging–detected lacunar infarcts and white matter lesions (96), and clinical stroke events (97,98). In the Cardiovascular Health Study, wider retinal venular caliber was predictive of incident coronary heart disease (rate
ratio 3.0 [95% CI 1.6–5.7]; comparing largest to smallest venular caliber quartile) and incident stroke (2.2 [1.1–4.3]), whereas
narrower arteriolar caliber was predictive of incident coronary heart disease (2.0 [1.1–3.7]; comparing smallest to largest
arteriolar caliber quartile) (98). These findings suggest that both wider venular caliber and narrower arteriolar caliber may be markers of early subclinical
cardiovascular disease.
CHANGES IN RETINAL VASCULAR ARCHITECTURE—
New imaging methods have allowed the measurement of other architectural changes in the retinal microvasculature. Hypertension,
for example, has been associated with an increase in the retinal arteriolar length-to-diameter ratio (99,100), increased retinal venular tortuosity (99), reduced branching angle at arteriole bifurcations (101), and reduced microvascular density (99,101,102).
Some of these retinal changes have also been shown to be associated with increased cardiovascular risk. For example, the Beaver
Dam Study demonstrated that suboptimal arteriolar bifurcation and decreased arteriolar tortuosity are associated with coronary
heart mortality (103).
IMPLICATIONS FOR RESEARCH AND CLINICAL MANAGEMENT—
It is now well recognized that individuals with impaired glucose metabolism or pre-diabetes have higher mortality from cardiovascular
disease (104–106). Similarly, individuals with high to normal blood pressure or prehypertension (107) are more likely to develop cardiovascular events (108,109). To permit appropriate preventative strategies, there is therefore great interest in early detection of individuals with
pre-diabetes and prehypertension.
This review suggests that retinal image analysis offers a novel noninvasive measurement of early changes in the vasculature—not
detectable on routine clinical examination—that may allow the identification of individuals at risk of diabetes and hypertension
and their subsequent complications. Retinal vascular imaging might also permit physicians to optimize management of individuals
with established diabetes and/or hypertension. For example, retinal vascular imaging may allow monitoring of chronic variations
in glucose and blood pressure, as well as the presence and severity of subclinical microvascular damage. However, a number
of issues should be resolved before retinal vascular imaging can be utilized in clinical practice.
First, despite a large body of data on the associations and risk prediction of retinal vascular caliber measurement in different
population-based studies, there is no accepted standardized classification of retinal vascular changes, and a lack of age-,
sex-, body size–, and blood pressure–specific normative data. New studies of retinal vascular changes in children, who are
generally free of many systemic conditions, may provide these reference data (21,110).
Second, for retinal vascular imaging to be useful for risk stratification, there must be a demonstration of independent predictive
value that substantially adds to traditional methods. This has not been conclusively demonstrated. Different analytical methods
have hampered the comparison of results between studies, and application-common methods in different studies will allow data
pooling to generate more valid risk estimates. Additionally, the role of novel measures of retinal vascular structure (99,103,111–113) in predicting diseases remains to be determined.
Third, the predictive value of retinal vascular imaging is currently based on associations seen in large population-based
samples (114–117). It is unclear whether the retinal measurements are sufficiently precise to differentiate risk at an individual level.
Finally, it is unknown whether modification of risk factors (e.g., increased physical activity, reduction in weight) or institution
of treatment (e.g., diabetes and antihypertensive medications) may improve retinal vascular measures and whether this is associated
with lowered risks of diabetes, hypertension, and their complications. This remains an important area of future research.
In conclusion, measurement of retinal vascular changes using new imaging techniques offers great potential to advance our
understanding of the early pathophysiological pathways of diabetes and hypertension development. Recent studies support the
concept that the retinal vasculature provides a summary measure of lifetime exposure to various processes involved in the
development of diabetes and hypertension. Furthermore, these studies suggest that the effects of glucose and blood pressure
on the retinal microvasculature are graded and continuous, and our current definitions of diabetic and hypertensive retinopathy
are arbitrary and do not capture early disease. Future research is clearly needed to assess the ability of retinal vascular
imaging to provide clinically useful information that adds to existing risk prediction models of diabetes and hypertension.
Figure 1—
Prevalence of retinopathy in nondiabetic populations (A) and nondiabetic and nonhypertensive populations (B). AusDiab: Australian Diabetes, Obesity and Lifestyle Study (year began: 1999–2000, n = 2,177, aged ≥25 years) (2); ARIC (year began: 1987–1990, n = 10,954, aged 48–73 years) (22); BDES: Beaver Dam Eye Study (year began: 1988–1990, n = 4,926, aged 43–84 years) (15); BMES: Blue Mountain Eye Study (year began: 1992–1994, n = 3,654, aged 49–97 years) (13); CHS: Cardiovascular Health Study (year began: 1989–1990, n = 2,050, aged 67–97 years) (14), Hoorn (year began: 1989–1992, n = 626, aged 50–74 years) (23), Rotterdam (year began: 1990–1993, n = 6,191, aged 55–99 years) (44), and Funagata (year began: 2000–2002, n = 1,481, aged ≥35 years) (24).
Table 1—
Associations of retinal vascular changes with diabetes, hypertension, and cardiovascular diseases
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 26 June 2007. DOI: 10.2337/dc07-0732.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted June 20, 2007.
- Received April 15, 2007.
- DIABETES CARE
References
- ↵
Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.
Diabetes Care
26:
2653–2664, 2003
- ↵
Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, Taylor HR, Welborn TA, Zimmet PZ: The prevalence of and
factors associated with diabetic retinopathy in the Australian population. Diabetes Care 26:1731–1737, 2003
- ↵
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic
retinopathy. JAMA 260:2864–2871, 1988
- ↵
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent
diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986, 1993
- ↵
The UK Propsective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998
- ↵
The UK Propsective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications
in type 2 diabetes: UKPDS 38. BMJ 317:703–713, 1998
- ↵
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA,
Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M: Effects of long-term fenofibrate therapy on cardiovascular
events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861, 2005
- ↵
Wong TY, Mitchell P: Hypertensive retinopathy. N Engl J Med 351:2310–2317, 2004
- ↵
Wong T, Mitchell P: The eye in hypertension. Lancet 369:425–435, 2007
- ↵
Leung H, Wang JJ, Rochtchina E, Tan AG, Wong TY, Klein R, Hubbard LD, Mitchell P: Relationships between age, blood pressure,
and retinal vessel diameters in an older population. Invest Ophthalmol Vis Sci 44:2900–2904, 2003
-
Sharp PS, Chaturvedi N, Wormald R, McKeigue PM, Marmot MG, Young SM: Hypertensive retinopathy in Afro-Caribbeans and Europeans:
prevalence and risk factor relationships. Hypertension 25:1322–1325, 1995
-
Wang JJ, Mitchell P, Leung H, Rochtchina E, Wong TY, Klein R: Hypertensive retinal vessel wall signs in a general older population:
the Blue Mountains Eye Study. Hypertension 42:534–541, 2003
- ↵
Yu T, Mitchell P, Berry G, Li W, Wang JJ: Retinopathy in older persons without diabetes and its relationship to hypertension.
Arch Ophthalmol 116:83–89, 1998
- ↵
Wong TY, Klein R, Sharrett AR, Manolio TA, Hubbard LD, Marino EK, Kuller L, Burke G, Tracy RP, Polak JF, Gottdiener JS, Siscovick
DS: The prevalence and risk factors of retinal microvascular abnormalities in older persons: the Cardiovascular Health Study.
Ophthalmology 110:658–666, 2003
- ↵
Klein R, Klein BE, Moss SE, Wang Q: Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population.
Arch Ophthalmol 112:92–98, 1994
- ↵
Klein R, Klein BE, Moss SE: The relation of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye
Study. Trans Am Ophthalmol Soc 95:329–348, 1997
- ↵
Klein R, Sharrett AR, Klein BE, Chambless LE, Cooper LS, Hubbard LD, Evans G: Are retinal arteriolar abnormalities related
to atherosclerosis? The Atherosclerosis Risk in Communities Study. Arterioscler Thromb Vasc Biol 20:1644–1650, 2000
- ↵
Sharrett AR, Hubbard LD, Cooper LS, Sorlie PD, Brothers RJ, Nieto FJ, Pinsky JL, Klein R: Retinal arteriolar diameters and
elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 150:263–270, 1999
-
Duncan BB, Wong TY, Tyroler HA, Davis CE, Fuchs FD: Hypertensive retinopathy and incident coronary heart disease in high risk
men. Br J Ophthalmol 86:1002–1006, 2002
- ↵
Wong TY, Islam FM, Klein R, Klein BE, Cotch MF, Castro C, Sharrett AR, Shahar E: Retinal vascular caliber, cardiovascular
risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci 47:2341–2350, 2006
- ↵
Mitchell P, Cheung N, de Haseth K, Taylor B, Rochtchina E, Islam FMA, Wang JJ, Saw SM, Wong TY: Blood pressure and retinal
arteriolar narrowing in children. Hypertension 49:1156–1162, 2007
- ↵
Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, Davis MD, Cai J: Methods for evaluation of retinal
microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 106:2269–2280, 1999
- ↵
van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC: Blood pressure, lipids, and obesity
are associated with retinopathy: the Hoorn Study. Diabetes Care 25:1320–1325, 2002
- ↵
Kawasaki R, Wang JJ, Rochtchina E, Taylor B, Wong TY, Tominaga M, Kato T, Daimon M, Oizumi T, Kawata S, Kayama T, Yamashita
H, Mitchell P: Cardiovascular risk factors and retinal microvascular signs in an adult Japanese population: the Funagata Study.
Ophthalmology 113:1378–1384, 2006
- ↵
Couper DJ, Klein R, Hubbard LD, Wong TY, Sorlie PD, Cooper LS, Brothers RJ, Nieto FJ: Reliability of retinal photography in
the assessment of retinal microvascular characteristics: the Atherosclerosis Risk in Communities Study. Am J Ophthalmol 133:78–88, 2002
-
Sherry LM, Wang JJ, Rochtchina E, Wong T, Klein R, Hubbard L, Mitchell P: Reliability of computer-assisted retinal vessel
measurement in a population. Clin Experiment Ophthalmol 30:179–182, 2002
- ↵
Li H, Hsu W, Lee ML, Wong TY: Automatic grading of retinal vessel caliber. IEEE Trans Biomed Eng 52:1352–1355, 2005
- ↵
Wong TY, Knudtson MD, Klein R, Klein BE, Meuer SM, Hubbard LD: Computer-assisted measurement of retinal vessel diameters in
the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology 111:1183–1190, 2004
- ↵
Wagener HP, Clay GE, Gipner JF: Classification of retinal lesions in the presence of vascular hypertension: report submitted
to the American Ophthalmological Society by the committee on Classification of Hypertensive Disease of the Retina. Trans Am Ophthalmol Soc 45:57–73, 1947
- ↵
Parr JC, Spears GF: General caliber of the retinal arteries expressed as the equivalent width of the central retinal artery.
Am J Ophthalmol 77:472–477, 1974
- ↵
Parr JC, Spears GF: Mathematic relationships between the width of a retinal artery and the widths of its branches. Am J Ophthalmol 77:478–483, 1974
- ↵
Wong TY, Klein R, Klein BE, Meuer SM, Hubbard LD: Retinal vessel diameters and their associations with age and blood pressure.
Invest Ophthalmol Vis Sci 44:4644–4650, 2003
- ↵
Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR, Sharrett AR: Retinal microvascular abnormalities
and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 358:1134–1140, 2001
- ↵
Mitchell P, Wang JJ, Wong TY, Smith W, Klein R, Leeder SR: Retinal microvascular signs and risk of stroke and stroke mortality.
Neurology 65:1005–1009, 2005
- ↵
Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BE, Hubbard LD: Retinal arteriolar narrowing and risk
of coronary heart disease in men and women: the Atherosclerosis Risk in Communities Study. JAMA 287:1153–1159, 2002
- ↵
Patton N, Aslam T, Macgillivray T, Dhillon B, Constable I: Asymmetry of retinal arteriolar branch widths at junctions affects
ability of formulae to predict trunk arteriolar widths. Invest Ophthalmol Vis Sci 47:1329–1333, 2006
- ↵
Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de Jong PT: Are retinal arteriolar or venular diameters
associated with markers for cardiovascular disorders? The Rotterdam Study. Invest Ophthalmol Vis Sci 45:2129–2134, 2004
- ↵
Liew G, Sharrett AR, Kronmal R, Klein R, Wong TY, Mitchell P, Kifley A, Wang JJ: Measurement of retinal vascular caliber:
issues and alternatives to using the arteriole to venule ratio. Invest Ophthalmol Vis Sci 48:52–57, 2007
- ↵
Liew G, Wong TY, Mitchell P, Wang JJ: Are narrower or wider retinal venules associated with incident hypertension? Hypertension 48:e10, 2006
- ↵
Patton N, Aslam TM, MacGillivray T, Deary IJ, Dhillon B, Eikelboom RH, Yogesan K, Constable IJ: Retinal image analysis: concepts,
applications and potential. Prog Retin Eye Res 25:99–127, 2006
- ↵
Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein
JI, Dawber TR: The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic
retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol 24:335–610, 1980
-
Svardsudd K, Wedel H, Aurell E, Tibblin G: Hypertensive eye ground changes: prevalence, relation to blood pressure and prognostic
importance: the study of men born in 1913. Acta Med Scand 204:159–167, 1978
- ↵
McDonough JR, Garrison GE, Hames CG: Blood pressure and hypertensive disease among negroes and whites: a study in Evans County,
Georgia. Ann Intern Med 61:208–228, 1964
- ↵
Stolk RP, Vingerling JR, de Jong PT, Dielemans I, Hofman A, Lamberts SW, Pols HA, Grobbee DE: Retinopathy, glucose, and insulin
in an elderly population: the Rotterdam Study. Diabetes 44:11–15, 1995
- ↵
Cugati S, Cikamatana L, Wang JJ, Kifley A, Liew G, Mitchell P: Five-year incidence and progression of vascular retinopathy
in persons without diabetes: the Blue Mountains Eye Study. Eye 20:1239–1245, 2006
- ↵
Wong TY, Barr EL, Tapp RJ, Harper CA, Taylor HR, Zimmet PZ, Shaw JE: Retinopathy in persons with impaired glucose metabolism:
the Australian Diabetes Obesity and Lifestyle (AusDiab) study. Am J Ophthalmol 140:1157–1159, 2005
- ↵
The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program.
Diabet Med 24:137–144, 2007
- ↵
Wong TY, Klein R, Islam FM, Cotch MF, Couper DJ, Klein BE, Hubbard L, Sharrett AR: Three-year incidence and cumulative prevalence
of retinopathy: the Atherosclerosis Risk in Communities Study. Am J Ophthalmol 143:970–976, 2007
- ↵
Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, Hubbard LD, Sharrett AR: Racial differences in the prevalence
of hypertensive retinopathy. Hypertension 41:1086–1091, 2003
- ↵
van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC, Stehouwer CD: Inflammation and endothelial dysfunction
are associated with retinopathy: the Hoorn Study. Diabetologia 48:1300–1306, 2005
- ↵
Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis
and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836–10841, 1999
-
Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, Rewers MJ, Garg SK: Inflammatory markers and diabetic retinopathy
in type 1 diabetes. Diabetes Care 28:714–715, 2005
- ↵
Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis
AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452, 2004
- ↵
Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15:815–819, 1992
- ↵
Cugati S, Mitchell P, Wang JJ: Do retinopathy signs in non-diabetic individuals predict the subsequent risk of diabetes? Br J Ophthalmol 90:928–929, 2006
- ↵
Wong TY, Mohamed Q, Klein R, Couper DJ: Do retinopathy signs in non-diabetic individuals predict the subsequent risk of diabetes?
Br J Ophthalmol 90:301–303, 2006
- ↵
Klein R, Klein BEK, Mos SE, Wong TY: The relationship of retinopathy in persons without diabetes to the 15-year incidence
of diabetes and hypertension: Beaver Dam Eye Study. Trans Am Ophthalmol Soc 104:98–107, 2006
- ↵
Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Klein BE, Hubbard LD, Nieto FJ: Retinal arteriolar diameter and risk
for hypertension. Ann Intern Med 140:248–255, 2004
- ↵
Wong TY, Rosamond W, Chang PP, Couper DJ, Sharrett AR, Hubbard LD, Folsom AR, Klein R: Retinopathy and risk of congestive
heart failure. JAMA 293:63–69, 2005
- ↵
Wong TY, Coresh J, Klein R, Muntner P, Couper DJ, Sharrett AR, Klein BE, Heiss G, Hubbard LD, Duncan BB: Retinal microvascular
abnormalities and renal dysfunction: the atherosclerosis risk in communities study. J Am Soc Nephrol 15:2469–2476, 2004
- ↵
Edwards MS, Wilson DB, Craven TE, Stafford J, Fried LF, Wong TY, Klein R, Burke GL, Hansen KJ: Associations between retinal
microvascular abnormalities and declining renal function in the elderly population: the Cardiovascular Health Study. Am J Kidney Dis 46:214–224, 2005
- ↵
Rema M, Mohan V, Deepa R, Ravikumar R: Association of carotid intima-media thickness and arterial stiffness with diabetic
retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes Care 27:1962–1967, 2004
- ↵
Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S: Diabetic retinopathy in a multi-ethnic cohort
in the United States. Am J Ophthalmol 141:446–455, 2006
- ↵
Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, Hubbard LD, Duncan BB: Retinal arteriolar narrowing
and risk of diabetes mellitus in middle-aged persons. JAMA 287:2528–2533, 2002
- ↵
Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD: Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes
mellitus. Arch Intern Med 165:1060–1065, 2005
- ↵
Ikram MK, Janssen JA, Roos AM, Rietveld I, Witteman JC, Breteler MM, Hofman A, van Duijn CM, de Jong PT: Retinal vessel diameters
and risk of impaired fasting glucose or diabetes: the Rotterdam Study. Diabetes 55:506–510, 2006
- ↵
Wong TY, Duncan BB, Golden SH, Klein R, Couper DJ, Klein BE, Hubbard LD, Sharrett AR, Schmidt MI: Associations between the
metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. Invest Ophthalmol Vis Sci 45:2949–2954, 2004
- ↵
Wang JJ, Taylor B, Wong TY, Chua B, Rochtchina E, Klein R, Mitchell P: Retinal vessel diameters and obesity: a population-based
study in older persons. Obesity (Silver Spring )14:206–214, 2006
- ↵
Cheung N, Saw SM, Islam FM, Rogers SL, Shankar A, de Haseth K, Mitchell P, Wong TY: BMI and retinal vascular caliber in children.
Obesity (Silver Spring )15:209–215, 2007
- ↵
Klein R, Klein BE, Moss SE, Wong TY, Sharrett AR: Retinal vascular caliber in persons with type 2 diabetes: the Wisconsin
Epidemiological Study of Diabetic Retinopathy: XX. Ophthalmology 113:1488–1498, 2006
- ↵
Klein R, Klein BE, Moss SE, Wong TY, Hubbard L, Cruickshanks KJ, Palta M: Retinal vascular abnormalities in persons with type
1 diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVIII. Ophthalmology 110:2118–2125, 2003
- ↵
Wong TY, Shankar A, Klein R, Klein BE: Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency
in people with type 1 diabetes. Diabetes 53:179–184, 2004
- ↵
Grunwald JE, Riva CE, Baine J, Brucker AJ: Total retinal volumetric blood flow rate in diabetic patients with poor glycemic
control. Invest Ophthalmol Vis Sci 33:356–363, 1992
- ↵
Saldivar E, Cabrales P, Tsai AG, Intaglietta M: Microcirculatory changes during chronic adaptation to hypoxia. Am J Physiol Heart Circ Physiol 285:H2064–H2071, 2003
- ↵
Caballero AE: Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous
situation. Arch Med Res 36:241–249, 2005
- ↵
Klein R, Klein BE, Knudtson MD, Wong TY, Tsai MY: Are inflammatory factors related to retinal vessel caliber? The Beaver Dam
Eye Study. Arch Ophthalmol 124:87–94, 2006
- ↵
Tamai K, Matsubara A, Tomida K, Matsuda Y, Morita H, Armstrong D, Ogura Y: Lipid hydroperoxide stimulates leukocyte-endothelium
interaction in the retinal microcirculation. Exp Eye Res 75:69–75, 2002
- ↵
Kolodjaschna J, Berisha F, Lung S, Schaller G, Polska E, Jilma B, Wolzt M, Schmetterer L: LPS-induced microvascular leukocytosis
can be assessed by blue-field entoptic phenomenon. Am J Physiol Heart Circ Physiol 287:H691–H694, 2004
- ↵
Wilkinson-Berka JL: Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and
nitric oxide. Curr Pharm Des 10:3331–3348, 2004
- ↵
Chester AH, Borland JA, Buttery LD, Mitchell JA, Cunningham DA, Hafizi S, Hoare GS, Springall DR, Polak JM, Yacoub MH: Induction
of nitric oxide synthase in human vascular smooth muscle: interactions between proinflammatory cytokines. Cardiovasc Res 38:814–821, 1998
- ↵
de Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI, Kritchevsky SB, Kuller LH, Strotmeyer ES, Schwartz AV, Vellas
B, Harris TB: Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study.
Diabetes Care 29:1902–1908, 2006
- ↵
Ling PR, Mueller C, Smith RJ, Bistrian BR: Hyperglycemia induced by glucose infusion causes hepatic oxidative stress and systemic
inflammation, but not STAT3 or MAP kinase activation in liver in rats. Metabolism 52:868–874, 2003
- ↵
Nguyen TT, Wong TY: Retinal vascular manifestations of metabolic disorders. Trends Endocrinol Metab 17:262–268, 2006
- ↵
Tso MO, Jampol LM: Pathophysiology of hypertensive retinopathy. Ophthalmology 89:1132–1145, 1982
- ↵
Walsh JB: Hypertensive retinopathy: description, classification, and prognosis. Ophthalmology 89:1127–1131, 1982
- ↵
Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P: Impact of current and past blood pressure on retinal arteriolar
diameter in an older population. J Hypertens 22:1543–1549, 2004
- ↵
Wong TY, Hubbard LD, Klein R, Marino EK, Kronmal R, Sharrett AR, Siscovick DS, Burke G, Tielsch JM: Retinal microvascular
abnormalities and blood pressure in older people: the Cardiovascular Health Study. Br J Ophthalmol 86:1007–1013, 2002
- ↵
Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD: Prospective cohort study of retinal vessel diameters and risk of hypertension.
BMJ 329:79, 2004
- ↵
Smith W, Wang JJ, Wong TY, Rochtchina E, Klein R, Leeder SR, Mitchell P: Retinal arteriolar narrowing is associated with 5-year
incident severe hypertension: the Blue Mountains Eye Study. Hypertension 44:442–447, 2004
- ↵
Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT: Retinal vessel diameters and risk of hypertension:
the Rotterdam Study. Hypertension 47:189–194, 2006
- ↵
Mulvany MJ: Are vascular abnormalities a primary cause or secondary consequence of hypertension? Hypertension 18:I52–I57, 1991
- ↵
Xing C, Klein BE, Klein R, Jun G, Lee KE, Iyengar SK: Genome-wide linkage study of retinal vessel diameters in the Beaver
Dam Eye Study. Hypertension 47:797–802, 2006
- ↵
Wang JJ, Wong TY: Genetic determinants of retinal vascular caliber: additional insights into hypertension pathogenesis. Hypertension 47:644–645,2006
- ↵
Ingelfinger JR: Pediatric antecedents of adult cardiovascular disease–awareness and intervention. N Engl J Med 350:2123–2126, 2004
- ↵
Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME: Growth in utero, blood pressure in childhood and adult life, and mortality
from cardiovascular disease. BMJ 298:564–567, 1989
- ↵
Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MM, De Jong PT: Retinal vessel diameters and cerebral small
vessel disease: the Rotterdam Scan Study. Brain 129:182–188, 2006
- ↵
Ikram MK, de Jong FJ, Bos MJ, Vingerling JR, Hofman A, Koudstaal PJ, de Jong PT, Breteler MM: Retinal vessel diameters and
risk of stroke: the Rotterdam Study. Neurology 66:1339–1343, 2006
- ↵
Wong TY, Kamineni A, Klein R, Sharrett AR, Klein BE, Siscovick DS, Cushman M, Duncan BB: Quantitative retinal venular caliber
and risk of cardiovascular disease in older persons: the cardiovascular health study. Arch Intern Med 166:2388–2394, 2006
- ↵
Hughes AD, Martinez-Perez E, Jabbar AS, Hassan A, Witt NW, Mistry PD, Chapman N, Stanton AV, Beevers G, Pedrinelli R, Parker
KH, Thom SA: Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension.
J Hypertens 24:889–894, 2006
- ↵
King LA, Stanton AV, Sever PS, Thom SA, Hughes AD: Arteriolar length-diameter (L:D) ratio: a geometric parameter of the retinal
vasculature diagnostic of hypertension. J Hum Hypertens 10:417–418,1996
- ↵
Stanton AV, Wasan B, Cerutti A, Ford S, Marsh R, Sever PP, Thom SA, Hughes AD: Vascular network changes in the retina with
age and hypertension. J Hypertens 13:1724–1728, 1995
- ↵
Kutschbach P, Wolf S, Sieveking M, Ittel TH, Schulte K, Reim M: Retinal capillary density in patients with arterial hypertension:
2-year follow-up. Graefes Arch Clin Exp Ophthalmol 236:410–414, 1998
- ↵
Witt N, Wong TY, Hughes AD, Chaturvedi N, Klein BE, Evans R, McNamara M, Thom SA, Klein R: Abnormalities of retinal microvascular
structure and risk of mortality from ischemic heart disease and stroke. Hypertension 47:975–981, 2006
- ↵
Sorkin JD, Muller DC, Fleg JL, Andres R: The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality:
data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:2626–2632, 2005
-
Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG: Relation between blood glucose and coronary mortality over 33 years
in the Whitehall Study. Diabetes Care 29:26–31, 2006
- ↵
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: the DECODE study
group: European Diabetes Epidemiology Group: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.
Lancet 354:617–621, 1999
- ↵
Gu D, Wildman RP, Wu X, Reynolds K, Huang J, Chen CS, He J: Incidence and predictors of hypertension over 8 years among Chinese
men and women. J Hypertens 25:517–523, 2007
- ↵
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella
EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:
the JNC 7 report. JAMA 289:2560–2572, 2003
- ↵
Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L, LaCroix AZ, Black HR: Prehypertension and cardiovascular disease
risk in the Women's Health Initiative. Circulation 115:855–860, 2007
- ↵
Cheung N, Islam FM, Saw SM, Shankar A, de Haseth K, Mitchell P, Wong TY: Distribution and associations of retinal vascular
caliber with ethnicity, gender, and birth parameters in young children. Invest Ophthalmol Vis Sci 48:1018–1024, 2007
- ↵
Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, Bousser MG, Heutink P, Miner JH, Tournier-Lasserve E, John
SW: Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 354:1489–1496, 2006
-
Gekeler F, Shinoda K, Junger M, Bartz-Schmidt KU, Gelisken F: Familial retinal arterial tortuosity associated with tortuosity
in nail bed capillaries. Arch Ophthalmol 124:1492–1494, 2006
- ↵
Muiesan ML, Grassi G: Assessment of retinal vascular changes in hypertension: new perspectives. J Hypertens 24:813–814, 2006
- ↵
Wong TY, Klein R, Nieto FJ, Klein BE, Sharrett AR, Meuer SM, Hubbard LD, Tielsch JM: Retinal microvascular abnormalities and
10-year cardiovascular mortality: a population-based case-control study. Ophthalmology 110:933–940, 2003
-
Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, Hubbard LD, Mosley TH: Cerebral white matter lesions, retinopathy,
and incident clinical stroke. JAMA 288:67–74, 2002
-
Wong TY, Mosley TH Jr, Klein R, Klein BE, Sharrett AR, Couper DJ, Hubbard LD: Retinal microvascular changes and MRI signs
of cerebral atrophy in healthy, middle-aged people. Neurology 61:806–811, 2003
- ↵
Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ, Mosley TH, Klein BE, Hubbard LD, Szklo M: Retinal microvascular
abnormalities and cognitive impairment in middle-aged persons: the Atherosclerosis Risk in Communities Study. Stroke 33:1487–1492, 2002
